Ipsen

Ipsen

Ipsen

Ipsen is driven by a passion to improve the lives of patients and search for innovative solutions to disabling conditions. Terms of use on our site
Founded
1929
Follow us
Alexa global traffic share
Twitter followers
Team Size
1000+
Employees
Location
Headquarters
MedCity News

Ipsen’s latest R&D alliance brings novel T cell-activating drugs for cancer

MedCity News

Ipsen’s $247M Epizyme acquisition brings approved cancer drug & more in pipeline

SiliconRepublic

Biopharma company Ipsen to invest €27m in Dublin manufacturing site

MedCity News

Ipsen gets rights to failed Genfit NASH drug, now in Phase 3 for rare liver disease

MedCity News

Ipsen bets on Exicure’s tech as better way to deliver neuro drugs deep into the brain

Xconomy

FDA Puts Partial Hold on Tests of Ipsen Drug Acquired in $1B Deal

Xconomy

Merrimack Hits Reset Button, Sells Cancer Drugs to Ipsen For $575M

Health Strategy Earnings